Complaints of cognitive changes are often expressed by patients at all stages of HIV infection. Such changes include decreased memory and attention span, diminished concentration, apathy, and “slowing.” Methylphenidate (MPD) has been used in several clinical studies in men with late-stage HIV disease in an attempt to ameliorate these difficulties. The objectives of this review article are to review salient psychopharmacological characteristics of MPD and to describe the research and clinical literature supporting the use of MPD in patients at all stages of HIV infection.
Methods:
Seven studies, case reports, or abstracts from International Conferences on AIDS were available in the English literature through August, 1993, directly addressing the use of MPD in patients with HIV disease. Twenty-nine papers were reviewed for pharmacokinetic data, eighteen for safety and side effects issues, and seventeen for relevant contributions from the neuropsychological testing literature.
Results:
Studies in clinical settings have used doses ranges from 10–90 mg. per day in two or three divided doses with reportedly good results in improving both affective and cognitive symptoms associated with HIV disease. Side effects have been relatively mild and patient satisfaction with treatment has been high. However, no studies have been conducted in early stage HIV disease, where a significant minority of patients have similar complaints in the absence of clinically apparent immunosuppression. Likewise, placebo-controlled, dose-finding studies in AIDS patients are entirely lacking, and no studies in women with HIV disease and cognitive changes have been published.
Conclusions:
In spite of these important research shortcomings, clinical experience with MPD treatment of cognitive changes in men with HIV/AIDS is consistent with the notion that this medication holds significant promise to improve the quality of life for persons living with HIV/AIDS. Controlled studies to test this hypothesis are warranted.
PaceJ.BrownG.RundellJ.PaolucciS.DrexlerK., and McManisS.Prevalence of Psychiatric Disorders in a Mandatory Screening Program for Infection with Human Immunodeficiency Virus: A Pilot Study, Military Medicine, 155: 76–80, 1990.
2.
DouzenisA.BrenerN.CatalanJ., and MeadowsJ., Psychiatric Disorder in HIV Disease: 200 Patients Referred to a Liaison Psychiatry Service, proceedings of the 7th International Conference on AIDS, Vol. 1, M.B. 2135:215, 1991.
3.
NaviaB.JordanB., and PriceR.. The AIDS Dementia Complex: I. Clinical Features, Annals of Neurology, 19: 517–524, 1986.
4.
BelyaevaV.SemenovichA.RoutchkinaY., and PokrovskyV., Phenomenology of Neuropsychological Deficiency in HIV Infected Individuals, Proceedings of the Ninth International Conference on AIDS, Berlin, Abstract PO-B16–1662, p. 412, 1993.
5.
PoutiainenE.IvanainenM.ElovaaraI.ValleS., and LahdevirtaJ.Cognitive Changes as Early Signs of HIV Infection, Acta Neurologica Scandinavica, 78: 49–52, 1988.
6.
PerdicesM. and CooperD.Simple and Choice Reaction Time in Patients with Human Immunodeficiency Virus, Annals of Neurology, 25: 260–267, 1989.
7.
PerdicesM. and CooperD.Neuropsychological Investigation of Patients with AIDS and ARC, Journal of Acquired Immune Deficiency Syndromes, 3: 555–564, 1990.
8.
KovnerR.PerecmanE.LazarW.HainlineB.KaplanM.LesserM., and BeresfordR.Relation of Personality and Attentional Factors to Cognitive Deficits in Human Immunodeficiency Virus-infected Subjects, Archives of Neurology, 46: 274–277, 1989.
9.
KoppelB.WormserG.TuchmanA.MaayanS.HewlettD., and DarasM.Central Nervous System Involvement in Patients with Acquired Immune Deficiency Syndrome (AIDS), Acta Neurologica Scandinavica, 71: 337–353, 1985.
10.
MarshallD.BreyR.CahillW.HoukR.ZajacR., and BoswellR.Spectrum of Cerebrospinal Fluid Findings in Various Stages of Human Immunodeficiency Virus Infection, Archives of Neurology, 45: 954, 958, 1988.
11.
McArthurJ.CohenB.FarzedeganH.CornblathD.SeinesO.OstrowD.JohnsonR.PhairJ., and PolkB.Cerebrospinal Fluid Abnormalities in Homosexual Men With and Without Neuropsychiatric Findings, Annals of Neurology, 23 (suppl): S34–S37, 1988.
12.
CollierA.MarraC.CoombsR.ClaypooleK.CohenW.LongstrethW.TownesB.MaravillaK.CritchlowC.MurphyV., and HandsfieldH.Central Nervous System Manifestations in Human Immunodeficiency Virus Infection without AIDS, Journal of Acquired Immune Deficiency Syndromes, 5: 229–241, 1992.
13.
HeyesM.RubinowD.LaneC., and MarkeyS.Cerebrospinal Fluid Quinolinic Acid Concentrations are Increased in Acquired Immune Deficiency Syndrome, Annals of Neurology, 26: 275–277, 1989.
14.
HeyesM.BrewB.MartinA.PriceR.SalazarA.SidtisJ.YergeyJ.MouradianM.SadlerA.KeilpJ.RubinowD., and MarkeyS.Quinolinic Acid in Cerebrospinal Fluid and Serum in HIV Infection: Relationship to Clinical and Neurologic Status, Annals of Neurology, 29: 202–209, 1991.
15.
PrausD.BrownG.RundellJ., and PaolucciS.Associations between Cerebrospinal Fluid Parameters and High Degrees of Anxiety or Depression in United States Air Force Personnel Infected with Human Immunodeficiency Virus, Journal of Nervous and Mental Disease, 178: 392–395, 1990.
16.
JanssenR.SaykinA.CannonL.CampbellJ.PinskyP.HessolN.O'MalleyB.LifsonA.DollL.RitherfordG., and KaplanJ.Neurological and Neuropsychological Manifestations of HIV-1 Infection: Association with AIDS-related Complex but not Asymptomatic HIV-1 Infection, Annals of Neurology, 26: 592–600, 1989.
17.
McArthurJ.CohenB.SeinesO.KumorA.CooperK.McArthurJ.SoucyG.CornblathD.ChmielJ.WangM.StarkeyD.GinzburgH.OstrowD.JohnsonR.PhairJ., and PolkB.Low Prevalence of Neurological and Neuropsychological Abnormalities in Otherwise Healthy HIV-1 Infected Individuals: Results from the Multicenter AIDS Cohort Study, Annals of Neurology, 26: 601–611, 1989.
18.
MillerE.SeinesO.McArthurJ.SatzP.BeckerJ.CohenB.SheridanK.MacHadoA.Van GropW., and VisscherB.Neuropsychological Performance in HIV-1 Infected Homosexual Men: The Multicenter AIDS Cohort Study (MACS), Neurology, 40: 197–203, 1990.
19.
MillerE.SelnesO., and VisscherB., Cognition in Asymptomatic HIV-1 Infection, Four-year Longitudinal Follow-up of AIDS-free Subjects in the Multicenter AIDS Cohort Study (MACS), proceedings of the Ninth International Conference on AIDS, Berlin, Abstract PO-B16–1739, 1993.
20.
SeinesO.MillerE.McArthurJ.HIV-1 Infection: No Evidence of Cognitive Decline during the Asymptomatic Stages, Neurology, 40: 204–206, 1990.
21.
LawW.MartinA.WilliamsJ.RollerT.KampenD., and SalazarA., The Beck Depression Inventory in HIV+ Infection: Independence of Cognitive Slowing from Psychiatric Symptoms, presented at Neurological and Neuropsychological Complications of HIV Infection, Monterey, California, 1990.
22.
McManisS.BrownG.ZacharyR., and RundellJ.A Screening Test for Subtle Cognitive Deficits in Early HIV Disease, Psychosomatics, 34: 424–431, 1993.
23.
GrantI.AtkinsonJ.HesselinkJ.KennedyC.RicmanD.SpectorS., and McCutchanJ.Evidence for Early Central Nervous System Involvement in the Acquired Immunodeficiency Syndrome (AIDS) and Other Human Immunodeficiency Virus (HIV) Infections, Annals of Internal Medicine, 107: 828–836, 1987.
24.
WilkieF.EisdorferC.MorganR.LoewensteinD., and SzapocznikL.Cognition in Early Human Immunodeficiency Virus Infection, Archives of Neurology, 47: 433–440, 1990.
25.
MartinA.KampenD.SalazarA.WilliamsJ.LawW., and RollerT., Slowed Cognitive Processing in HIV+ Patients in Comparison to Psychiatric Controls, presented at the Vth International Conference on AIDS, Montreal, Quebec, 1989.
26.
MartinA.HeyesM. P.SalazarA. M.Progressive Slowing of Reaction Time an Increasing Cerebrospinal Fluid Concentrations of Quinolinic Acid in HIV-infected Individuals, Journal of Neuropsychiatry and Clinical Neurosciences, 4: 270–279, 1992.
27.
PetitoC.Review of Central Nervous System Pathology in Human Immunodeficiency Virus Infection, Annals of Neurology, 23 (suppl): S54–S57, 1988.
28.
MesulamM., Attention, Confusional States, and Neglect, in Principles of Behavioral Neurology, MesulamM. M. (ed.), F. A. Davis, Philadelphia, 125–168, 1985.
29.
BrownG.RundellJ.McManisS.KendallS.ZacharyR., and TemoshokL.Prevalence of Psychiatric Disorders in Early Stages of HIV Infection in United States Air Force Personnel, Psychosomatic Medicine, 54: 588–601, 1992.
30.
BrownG.RundellJ.McManisS.KendallS., and JenkinsR.Neuropsychiatric Morbidity in Early HIV Disease: Implications for Military Occupational Function, Vaccine, 11: 560–569, 1993.
31.
WorthJ.SavageC., and NaviaB., Computer-based Measures of Neuropsychological Deficits in Patients with AIDS Dementia Complex, Proceedings of the 8th International AIDS Conference, Amsterdam, The Netherlands, Vol. 2, Abstract B223, 1992.
32.
HeatonR.VelinR.GrantI.GodfreyH.ChandlerJ.AtkinsonJ., and McCutchanA., Relationships between Neuropsychological Impairment and Vocational Functioning in HIV-infected Subjects, Proceedings of the First International Conference on the Biopsychosocial Aspects of HIV Infection, Amsterdam, The Netherlands, p. 123, 1990.
33.
MapouR.LawW.RollerT.WilliamsJ.KampenD.SalazarA., and MartinA., Awareness of Cognitive and Physical Deficits in HIV Infection, Proceedings of the First International Conference on Biopsychosocial Aspects of HIV Infection, Amsterdam, The Netherlands, p. 122, 1991.
34.
WoodsS.TesarG.MurrayG., and CassemN.Psychostimulant Treatment of Depressive Disorders Secondary to Medical Illness, Journal of Clinical Psychiatry, 47: 12–15, 1986.
35.
StiebelV. and KempK.Long-term Methylphenidate Use in the Medically Ill Patient with Organic Mood Syndrome, Psychosomatics, 31: 454–456, 1990.
36.
MasandP.PickettP., and MurrayG.Psychostimulants for Secondary Depression in Medical Illness, Psychosomatics, 32: 203–208, 1991.
37.
HolmesV.FernandezF., and LevyJ.Psychostimulant Response in AIDS-related Complex Patients, Journal of Clinical Psychiatry, 50: 5–8, 1989.
38.
FernandezF.LevyJ., and GalizziH.Response of HIV-related Depression to Psychostimulants: Case Reports, Hospital and Community Psychiatry, 39: 628–631, 1988a.
39.
FernandezF.AdamsF.LevyJ.HolmesV.NeidhartM., and MansellP.Cognitive Impairment Due to AIDS-related Complex and Its Response to Psychostimulants, Psychosomatics, 29: 38–46, 1988b.
40.
AngristB.D'HollosyM.SatrianoJ.SanfilipoM.DiamondG.SimberkoffM., and WeinrebH., Central Nervous System Stimulants as Symptomatic Treatment for AIDS Dementia Complex, 7th International Conference on AIDS, Vol. 1, p. 195. Florence, Italy, Abstract No. M.B. 2053, 1991.
41.
AngristB.D'HollosyM.SanfilipoM.SatrianoJ.DiamondG.SimberkoffM., and WeinrebH.Central Nervous System Stimulants as Symptomatic Treatments for AIDS-related Neuropsychiatric Impairment, Journal of Clinical Psychopharmacology, 12: 268–272, 1992.
42.
WhiteJ.ChristensenJ., and SingerC.Methylphenidate as a Treatment for Depression in Acquired Immunodeficiency Syndrome: An n-of-1 Trial, Journal of Clinical Psychiatry, 53: 153–156, 1992.
43.
BrownR. and SexsonS.A Controlled Trial of Methylphenidate in Black Adolescents: Attentional, Behavioral, and Physiological Effects, Clinical Pediatrics, 27: 74–81, 1988.
44.
TannockR.SchacharR.CarrR., and LoganG.Dose-response Effects of Methylphenidate on Academic Performance and Overt Behavior in Hyperactive Children, Pediatrics, 84: 648–657, 1989.
45.
PelhamW.WalkerJ.SturgesJ., and HozaJ.Comparative Effects of Methylphenidate on ADD Girls and ADD Boys, Journal of the American Academy of Child & Adolescent Psychiatry, 28: 773–776, 1989,.
46.
DouglasV.BarrR.AminK.O'NeillM., and BrittonB.Dosage Effects and Individual Responsivity to Methylphenidate in Attention Deficit Disorder, Journal of Child Psychology & Psychiatry & Allied Disciplines, 29: 453–475, 1988.
47.
MartinE.SorensenD.RobertsonL.EdelsteinH., and ChirurgiV.Special Attention in HIV-1 Infection: A Preliminary Report, Journal of Neuropsychiatry and Clinical Neurosciences, 4: 288–293, 1992a.
48.
MartinE.SorensenD.EdelsteinH., and RobertsonL.Decision-making Speed in HIV-1 Infection: A Preliminary Report, AIDS, 6: 109–113, 1992b.
49.
BernhardK.BuhlerU., and BickelM.The Biochemical Behavior of Phenyl-piperidyl-acetic Acid Methyl Ester, A Psychoanaleptic Drug, Helvetica Chemical Act, 42: 802, 1959.
50.
WarginW.PatrickK.KiltsC.GualtieriC.EllingtonK.MuellerR.KraemerG., and BreeseG.Pharmacokinetics of Methylphenidate in Man, Rat, and Monkey, Journal of Pharmacology & Experimental Therapeutics, 226: 382–386, 1983.
51.
BartlettM. and EggerH.Disposition and Metabolism of Methylphenidate in Dog and Man, Federation Proceedings, 31: 537, 1972.
52.
FarajB.IsrailiZ., and PerelJ.Metabolism and Disposition of Methylphenidate C14: Studies in Man and Animals, Journal of Pharmacology and Experimental Therapeutics, 191: 535–547, 1974.
53.
SchubertB.Detection and Identification of Methylphenidate in Human Urine and Blood Samples, Acta Chemica Scandinavica, 24: 433–438, 1970.
54.
PerelJ. and DaytonP., Methylphenidate, in Psychotherapeutic Drugs, UsdinE. and ForrestI. (eds.), Marcel Dekker, New York, 1287–1316, 1977.
55.
BarkleyR.DuPaulG., and McMurrayM.Attention Deficit Disorder With and Without Hyperactivity: Clinical Response to Three Dose Levels of Methylphenidate, Pediatrics, 87: 519–531, 1991.
56.
SpragueR. and SlatorE.Methylphenidate in Hyperkinetic Children: Differences in Dose Effects on Learning and Social Behavior, Science, 198: 1274–1276, 1977.
57.
MurrayJ.Psychophysiological Effects of Methylphenidate (Ritalin), Psychological Reports, 61: 315–336, 1987.
58.
Van KempenG.GoekoopJ.JongH.EdelbroekP., and De WolffF.The Plasma Level of Methylphenidate in the Single-dose Oral Methylphenidate Test, Biological Psychiatry, 28: 638–640, 1990.
59.
PatrickK.StraughnA.JarviE.BreeseG., and MeyerM.The Absorption of Sustained-release Methylphenidate Formulations Compared to an Immediate-release Formulation, Biopharmaceutics & Drug Disposition, 10: 165–171, 1989.
60.
BirmaherB.GreenhillL.CooperT.FriedJ., and MaminskiB.Sustained Release Methylphenidate: Pharmacokinetic Studies in ADDH Males, Journal of the American Academy of Child & Adolescent Psychiatry, 28: 768–772, 1989.
61.
FriersonR.WeyJ., and TablerJ.Psychostimulants for Depression in the Medically Ill, American Family Physician, 43: 163–170, 1991.
62.
ChanY.SwansonJ.SoldinS.ThiessenJ.MacLeodS., and LoganW.Methylphenidate Hydrochloride Given With or Before Breakfast: II. Effects on Plasma Concentration or Methylphenidate and Ritalinic Acid, Pediatrics, 72: 56–59, 1983.
63.
SwansonJ.SandmanC.DeutschC., and BarenM.Methylphenidate Hydrochloride Given With or Before Breakfast: I. Behavioral, Cognitive, and Electrophysiologic Effects, Pediatrics, 72: 49–55, 1983.
64.
PatrickK.CaldwellR.FerrisR., and BreeseG.Pharmacology of the Enantiomers of Threo-methylphenidate, Journal of Pharmacology & Experimental Therapeutics, 241: 152–158, 1987.
65.
SrinivasN.QuinnD.HubbardJ., and MidhaK.Stereoselective Disposition of Methylphenidate in Children with Attention Deficit Disorder, Journal of Pharmacology & Experimental Therapeutics, 241: 300–306, 1987.
66.
AoyamaT.KotakiH.HondaT., and NakagawaF.Kinetic Analysis of Enantiomers of Threo-methylphenidate and Its Metabolite in Two Healthy Subjects after Oral Administration as Determined by a Gas Chromatographic-mass Spectrometric Method, Journal of Pharmaceutical Sciences, 79: 465–469, 1990.
67.
SrinivasN.HubbardJ.QuinnD.KorchinskiE., and MidhaK.Extensive and Enantioselective Presystemic Metabolism of Dl-threo-methylphenidate in Humans, Progress in Neuro-Psychopharmacology & Biological Psychiatry, 15: 213–220, 1991.
68.
CoffeyB.ShaderR., and GreenblattD.Pharmacokinetics of Benzodiazepines and Psychostimulants in Children, Journal of Clinical Psychopharmacology, 3: 217–225, 1983.
69.
PelhamW.SturgesJ.HozaJ.SchmidtC.BijlsmaJ.MilichR., and MoorerS.Sustained Release and Standard Methylphenidate Effects on Cognitive and Social Behavior in Children with Attention Deficit Disorder, Pediatrics, 80: 491–501, 1987.
70.
GualtieriC.HicksR.PatrickK.SchroederS., and BreeseG.Clinical Correlates of Methylphenidate Blood Levels, Therapeutic Drug Monitoring, 6: 379–392, 1984.
71.
SaferD. and AllenR.Absence of Tolerance to the Behavioral Effects of Methylphenidate in Hyperactive and Inattentive Children, Journal of Pediatrics, 115: 1003–1008, 1989.
72.
SharmaR.JavaidJ.PandeyG.EastonM., and DavisJ.Pharmacological Effects of Methylphenidate on Plasma Homovanillic Acid and Growth Hormone, Psychiatry Research, 32: 9–17, 1990.
73.
GurianB. and RosowskyE.Low-dose Methylphenidate in the Very Old, Journal of Geriatric Psychiatry & Neurology, 3: 152–154, 1990.
74.
LarssonM.ErvikM.LundborkP.SundhV., and SvanborgA.Comparison between Methylphenidate and Placebo as Adjuvant in Care and Rehabilitation of Geriatric Patients, Comprehensive Gerontology. Section A, Clinical & Laboratory Sciences, 2: 53–59, 1988.
75.
FernandezF. and AdamsF.Methylphenidate Treatment of Patients with Head and Neck Cancer, Head and Neck Surgery, 8: 296–300, 1986.
76.
GualtieriC. and EvansR.Stimulant Treatment for the Neurobehavioural Sequelae of Traumatic Brain Injury, Brain Injury, 2: 273–290, 1988.
77.
PickettP.MasandP., and MurrayG.Psychostimulant Treatment of Geriatric Depressive Disorders Secondary to Medical Illness, Journal of Geriatric Psychiatry & Neurology, 3: 146–151, 1990.
78.
RosenbergP.AhmedI., and HurwitzS.Methylphenidate in Depressed Medically Ill Patients, Journal of Clinical Psychiatry, 52: 263–267, 1991.
79.
BarkleyR.McMurrayM.EdelbrockC., and RobbinsK.Side Effects of Methylphenidate in Children with Attention Deficit Hyperactivity Disorder: A Systemic, Placebo-controlled Evaluation, Pediatrics, 86: 184–192, 1990.
80.
EichlsederW.Ten Years of Experience with 1,000 Hyperactive Children in a Private Practice, Pediatrics, 76: 176–186, 1985.
81.
FernandezF.AdamsF., and HolmesV.Methylphenidate for Depressive Disorders in Cancer Patients, Psychosomatics, 28: 455–461, 1987.
82.
FischR.Methylphenidate for Medical In-patients, International Journal of Psychiatry in Medicine, 15: 75–79, 1985–86.
83.
GolinkoB.Side Effects of Dextroamphetamines and Methylphenidate in Hyperactive Children—A Brief Review, Progress in Neuro-Psychopharmacology & Biological Psychiatry, 8: 1–8, 1984.
84.
BrownR. and SexsonS.Effects of Methylphenidate on Cardiovascular Responses in Attention Deficit Hyperactivity Disordered Adolescents, Journal of Adolescent Health Care, 10: 179–183, 1989.
85.
KellyK.RapportM., and DuPaulG.Attention Deficit Disorder and Methylphenidate: A Multi-step Analysis of Dose-response Effects on Children's Cardiovascular Functioning, International Clinical Psychopharmacology, 3: 167–181, 1988.
86.
BrownR.WynneM., and SlimmerL.Attention Deficit Disorder and the Effect of Methylphenidate on Attention, Behavioral, and Cardiovascular Functioning, Journal of Clinical Psychiatry, 45: 473–476, 1984.
87.
LucasP.GardnerD.WolkowitzO.TuckerE., and CowdryR.Methylphenidate-induced Cardiac Arrhythmias [letter], New England Journal of Medicine, 315: 1485, 1986.
88.
SchmittF.BigleyJ.McKinnisR.LogueP.EvansR., and DruckerJ.Neuropsychological Outcome of Zidovudine (AZT) Treatment of Patients with AIDS and AIDS-Related Complex, New England Journal of Medicine, 319: 1573–1578, 1988.
89.
PortegiesP.GansJ.LangeJ.DerixM.SpeelmandH.BakkerM.DannerS., and GoudsmitJ.Declining Incidence of AIDS Dementia Complex after Introduction of Zidovudine Treatment, British Medical Journal, 299: 819–821, 1989.
90.
KertznerR.MayeuxR.SternY.WilliamsJ.RabkinJ., and GormanJ., Effects of Zidovudine on Psychiatric and Neurological Variables, Proceedings of the 8th International AIDS Conference, Vol. 1, Abstract PoB 3772, Amsterdam, The Netherlands, 1992.
91.
ButtersN.GrantI.HaxzbyJ.JuddL.MartinA.McClellandJ.PequegnatW.SchachterD., and StoverE.Assessment of AIDS-related Cognitive Changes: Recommendations of the NIMH Workshop on Neuropsychological Assessment Approaches, Journal of Clinical and Experimental Neuropsychology, 12: 963–978, 1990.
92.
RosvoldH.MirskyA.SarasonI.A Continuous Performance Test of Brain Damage, Journal of Consulting and Clinical Psychology, 20: 343–350, 1956.
93.
MichaelR.KlormanR.SalzmanL.Normalizing Effects of Methylphenidate on Hyperactive Children's Vigilance Performance and Evoked Potentials, Psychophysiol, 18: 665–677, 1981.
94.
KlormanR.SalzmanL.BauerL.Effects of Two Doses of Methylphenidate on Cross-situational and Borderline Hyperactive Children's Evoked Potentials, Electroencephalography and Clinical Neurophysiology, 56: 169–184, 1983.
95.
KlormanR.BrumaghimJ.SalzmanL.Effects of Methylphenidate on Attention-deficit Hyperactivity Disorder With and Without Aggressive/noncompliant Features, Journal of Abnormal Psychology, 97: 413–422, 1988.
96.
KlormanR.BrumaghimJ.FitzpatrickP., and BorgstedtA.Methylphenidate Speeds Evaluation Processes of Attention Deficit Disorder Adolescents During a Continuous Performance Test, Journal of Abnormal Child Psychology, 19: 263–283, 1991.
97.
HinshawS.HenkerB.WhalenC.ErhardtD., and DunningtonR.Aggressive, Prosocial, and Nonsocial Behavior in Hyperactive Boys: Dose Effects of Methylphenidate in Naturalistic Settings, Journal of Consulting & Clinical Psychology, 57: 636–643, 1989.
98.
PelhamW.BenderM., and CaddellJ.Methylphenidate and Children with Attention Deficit Disorder: Dose Effects on Classroom Academic and Social Behavior, Archives of General Psychiatry, 42: 948–952, 1985.
99.
CunninghamC.SiegelL., and OffordD.A Dose-response Analysis of the Effects of Methylphenidate on the Peer Interactions and Simulated Classroom Performance of ADD Children With and Without Conduct Problems, Journal of Child Psychology & Psychiatry & Allied Disciplines, 32: 439–452, 1991.
100.
RapportM.DuPaulG.StonerG., and JonesT.Comparing Classroom and Clinic Measures of Attention Deficit Disorder: Differential Idiosyncratic, and Dose-response Effects of Methylphenidate, Journal of Consulting and Clinical Psychology, 54: 334–341, 1986.
101.
PeloquinL. and KlormanR.Effects of Methylphenidate on Normal Children's Mood, Event-related Potentials and Performance in Memory Scanning and Vigilance, Journal of Abnormal Psychology, 95: 88–98, 1986.
102.
CoonsH.PeloquinL.KlormanR.Effect of Methylphenidate on Young Adults' Vigilance and Event-related Potentials, Electroencephalography and Clinical Neurophysiology, 51: 373–387, 1981.
103.
RosciM.PigoriniF.BernabeiA.PauF.VolpiniV.MeriglianoD., and MeligranaM.Methods for Detecting Early Signs of AIDS Dementia Complex in Asymptomatic HIV-1 Infected Subjects, AIDS, 6: 1309–1316, 1992.
104.
BrownG. and RundellJ.Prospective Study of Psychiatric Aspects of Early HIV Infection in Women, General Hospital Psychiatry, 15: 139–147, 1993.
105.
FernandezF., Neuropsychiatric Syndromes and Their Treatment, in HIV Infection, in A Psychiatrist's Guide to AIDS and HIV Disease: AIDS Primer, American Psychiatric Association AIDS Education Project, Washington, D.C., 1990.
106.
NightingaleS.Parallel Track Policy Issued, Journal of the American Medical Association, 267: 3262, 1992.
